Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677768 · ClinicalTrials.gov registry record
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 475
- Enrollment target
NCT00677768: Completed study, sponsored by Massachusetts General Hospital.
NCT00677768 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 475 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00677768 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 475 participants
- Enrollment target
Study Summary
The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression. Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2008-04 |
| Est. Completion | 2015-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677768
The ClinicalTrials.gov registry entry for NCT00677768 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT00677768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00677768 about?
NCT00677768 is a clinical study titled "Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison o...
What is the current status of trial NCT00677768?
This trial is currently completed. The enrollment target is 475 participants. The study started on 2008-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00677768?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT00677768?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.